| 2026-09-02 |
Sellas Life Sciences Group |
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer sellaslifesciences.com ↗ |
| 2026-03-17 |
Sellas Life Sciences Group |
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference sellaslifesciences.com ↗ |
| 2026-03-12 |
Sellas Life Sciences Group |
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 sellaslifesciences.com ↗ |
| 2026-01-14 |
Sellas Life Sciences Group |
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe sellaslifesciences.com ↗ |
| 2025-12-07 |
Sellas Life Sciences Group |
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 sellaslifesciences.com ↗ |
| 2025-11-03 |
Sellas Life Sciences Group |
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting sellaslifesciences.com ↗ |
| 2025-10-13 |
Sellas Life Sciences Group |
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 sellaslifesciences.com ↗ |
| 2025-09-30 |
Sellas Life Sciences Group |
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update sellaslifesciences.com ↗ |
| 2025-07-15 |
Sellas Life Sciences Group |
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study sellaslifesciences.com ↗ |
| 2025-06-02 |
Sellas Life Sciences Group |
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting sellaslifesciences.com ↗ |
| 2025-05-15 |
Sellas Life Sciences Group |
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML sellaslifesciences.com ↗ |
| 2025-04-28 |
Sellas Life Sciences Group |
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference sellaslifesciences.com ↗ |
| 2025-04-08 |
Sellas Life Sciences Group |
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML sellaslifesciences.com ↗ |
| 2025-02-20 |
Sellas Life Sciences Group |
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL sellaslifesciences.com ↗ |
| 2024-12-09 |
Sellas Life Sciences Group |
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML sellaslifesciences.com ↗ |
| 2024-11-27 |
Sellas Life Sciences Group |
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers sellaslifesciences.com ↗ |
| 2024-08-06 |
Sellas Life Sciences Group |
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas sellaslifesciences.com ↗ |
| 2024-07-16 |
Sellas Life Sciences Group |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia sellaslifesciences.com ↗ |
| 2024-07-08 |
Sellas Life Sciences Group |
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia sellaslifesciences.com ↗ |
| 2024-06-24 |
Sellas Life Sciences Group |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia sellaslifesciences.com ↗ |
| 2024-06-10 |
Sellas Life Sciences Group |
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML sellaslifesciences.com ↗ |
| 2024-05-01 |
Sellas Life Sciences Group |
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level sellaslifesciences.com ↗ |
| 2024-03-26 |
Sellas Life Sciences Group |
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study sellaslifesciences.com ↗ |
| 2024-03-01 |
Sellas Life Sciences Group |
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference sellaslifesciences.com ↗ |
| 2024-02-29 |
Sellas Life Sciences Group |
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time sellaslifesciences.com ↗ |
| 2024-02-06 |
Sellas Life Sciences Group |
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget sellaslifesciences.com ↗ |
| 2024-01-25 |
Sellas Life Sciences Group |
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference sellaslifesciences.com ↗ |
| 2024-01-09 |
Sellas Life Sciences Group |
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients sellaslifesciences.com ↗ |
| 2023-12-21 |
Sellas Life Sciences Group |
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas sellaslifesciences.com ↗ |
| 2023-12-14 |
Sellas Life Sciences Group |
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia sellaslifesciences.com ↗ |
| 2023-10-30 |
Sellas Life Sciences Group |
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas sellaslifesciences.com ↗ |
| 2023-10-16 |
Sellas Life Sciences Group |
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia sellaslifesciences.com ↗ |
| 2023-10-11 |
Sellas Life Sciences Group |
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas sellaslifesciences.com ↗ |
| 2023-10-10 |
Sellas Life Sciences Group |
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia sellaslifesciences.com ↗ |
| 2023-09-21 |
Sellas Life Sciences Group |
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met sellaslifesciences.com ↗ |
|